3 reproductive health medicines prequalified, including first magnesium sulfate product

Aug 16, 2016 | WHO PQ

First magnesium sulfate product WHO prequalified

Concept Foundation is pleased to announce that Inresa Arzneimittel GmbH have achieved WHO prequalification on 15 August 2016 for their magnesium sulfate heptahydrate (MgSO4) 500 mg/ml injection with technical assistance from Concept Foundation.

Such support was provided under the auspices  of the United Nations Commission on Life-Saving commodities for Women and Children (UNCoLSC) and Packard Foundation, as well as through Jhpiego’s sub-award funded by the USAID-Accelovate program, which came as a supplementary grant to specifically support Concept Foundation’s activities with magnesium sulfate manufacturers, who are willing and able to work towards WHO Prequalification of this medicine.

The availability of this first WHO prequalified magnesium sulfate product marks an important milestone in the field of maternal health as this medicine is used to treat pre-eclampsia/eclampsia, the second most common cause of maternal deaths worldwide.

Third mifepristone product prequalified

Also on the 15th of August, a third mifepristone product was WHO prequalified for use in combination with misoprostol. This mifepristone 200mg tablet is manufactured by China Resources Zizhu, with technical assistance from Concept Foundation.

First levonorgestrel 30mcg product prequalified

Jai Pharma Ltd. in India have had their levonorgestrel 0.03mg tablets prequalified by the WHO. This is the first such generic progestin-only contraceptive to achieve prequalification.